In PBMC, IFNα treatment upregulated miR-29c-3p (upregulated in serum of COVID-19 patients), which is known to target the IFN receptor IFNAR1 as negative feedback to limit type I IFN response (76), as well as miR-146a-5p and miR-378a-3p, which, respectively, inhibit TLR-mediated innate immune responses (11) and promote NET formation by granulocytes in sepsis (77). This evidence concerns the gene IFNA1 and COVID-19.